Nephrology Drugs Market Report 2026

The nephrology drugs market size has grown strongly in recent years. It will grow from $17.69 billion in 2025 to $18.74 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to early adoption of antihypertensive agents, increasing cases of chronic kidney disease, growing hospital infrastructure for renal care, advancements in dialysis and parenteral treatments, rising awareness of kidney-related disorders.

The nephrology drugs market size is expected to see strong growth in the next few years. It will grow to $24.32 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to development of precision medicine for nephrology, integration of ai in renal drug development, expansion of homecare treatment solutions, rising investment in biotechnology for kidney therapies, adoption of digital health monitoring for kidney patients. Major trends in the forecast period include personalized kidney care solutions, rising prevalence of hypertension-related kidney disorders, advancements in renal drug formulations, growing awareness of chronic kidney disease management, increased adoption of home-based renal treatments.

The increasing prevalence of chronic kidney disease is anticipated to drive the growth of the nephrology drugs market in the coming years. Chronic kidney disease (CKD) refers to a condition in which the kidneys are damaged and unable to filter blood as efficiently as they should, as the damage develops slowly over an extended period. As a result, waste materials can build up in the body. Nephrology drugs are mainly used to treat chronic kidney disease by improving kidney function and slowing disease progression, thereby preventing further damage to the body, and these factors are contributing to the expansion of the nephrology drugs market. For instance, in June 2023, according to Oxford Academic, a UK-based academic research platform of Oxford University Press, the prevalence of CKD in the UK is expected to increase by 4%, from 8.27 million to 8.61 million people between 2022 and 2032, with the stage distribution in 2032 projected to be 30.36% for stage 1, 21.07% for stage 2, 29.78% for stage 3a, 11.86% for stage 3b, 4.15% for stage 4, and 2.78% for stage 5. Therefore, the rising prevalence of chronic kidney disease is fueling the growth of the nephrology drugs market.

Leading companies operating in the nephrology drugs market are concentrating on obtaining approvals for innovative products, such as the U.S. Food and Drug Administration approval of Jardiance (empagliflozin), to better address the needs of their existing customers. Empagliflozin is a diabetic medication used to manage and treat type 2 diabetes mellitus and belongs to the sodium-glucose co-transporter (SGLT-2) class of diabetic drugs. It lowers blood sugar levels by promoting the excretion of excess glucose through the urine via the kidneys. For example, in January 2023, Eli Lilly and Company, a US-based pharmaceutical company, along with Boehringer Ingelheim, announced that the Food and Drug Administration approved a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets, which are being studied as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD). Boehringer Ingelheim is a pharmaceutical company based in Germany.

In January 2024, Novartis AG, a Switzerland-based pharmaceutical company, acquired SanReno Therapeutics for an undisclosed sum. This acquisition highlights Novartis’ commitment to strengthening its presence in the renal market, particularly in Greater China and Singapore, where there is considerable growth potential for nephrology therapeutics. The strategic acquisition also supports Novartis’ broader objective of advancing innovative treatments for kidney diseases and reinforcing its competitive position in the nephrology drugs market. SanReno Therapeutics is a China-based clinical-stage biotechnology company focused on developing innovative therapies for kidney diseases, especially Immunoglobulin A Nephropathy (IgAN).

Major companies operating in the nephrology drugs market are AstraZeneca plc, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., FibroGen Inc., Johnson And Johnson, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vifor Pharma Group, Bayer AG, Otsuka Pharmaceutical Co. Ltd., Mylan N.V.

North America was the largest region in the nephrology drug market in 2025. Europe will be the second-largest growing region in the nephrology drug market in 2025. The regions covered in the nephrology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nephrology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the nephrology drugs market by increasing the cost of imported raw materials, active pharmaceutical ingredients (APIs), and finished renal medications. This has led to higher production costs, particularly affecting antihypertensive agents, erythropoiesis-stimulating agents, and diuretics. Regions such as Asia-Pacific, where manufacturing and export hubs like China and India dominate, are most affected. However, tariffs have also encouraged local production and innovation, driving development of cost-effective renal drugs and alternative supply strategies.

The nephrology drugs market research report is one of a series of new reports that provides nephrology drugs market statistics, including nephrology drugs industry global market size, regional shares, competitors with a nephrology drugs market share, detailed nephrology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the nephrology drugs industry. This nephrology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nephrology drugs, also referred to as renal drugs, are medications used in the management and treatment of kidney-related conditions. These drugs are often associated with the control of high blood pressure and hypertension and are used to improve kidney function, slow disease progression, and prevent further damage to the body.

The main types of drugs used in nephrology include antihypertensive agents, erythropoiesis-stimulating agents, diuretics, ACE inhibitors, antidiabetic agents, and others. Antihypertensive agents are a class of medications used to manage high blood pressure and act through various mechanisms to control hypertension. These drugs are administered through different routes such as oral, parenteral, and other methods, and are distributed via hospital pharmacies, online pharmacies, and retail pharmacies. The primary end users of nephrology drugs include hospitals, homecare settings, specialty clinics, and other healthcare providers.

The nephrology drugs market consists of sales of invokana, phoslo, renvela, sensipar, and procrit drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.